I have sold out my VKTX (common and calls) for a small profit. Position: None
Read in context ›Viking Therapeutics Stock (VKTX)
Track Viking Therapeutics stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
VKTX
Viking Therapeutics
healthcare
$29.22
▲ +1.41 (+5.07%) past year
Market Cap
$3.30B
P/E Ratio
—
1Y Return
+5.07%
EPS (TTM)
-$4.15
Read the latest TheStreet Pro articles mentioning Viking Therapeutics, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
61 articlesDaily Diary Mentions
25 mentionsOut of Viking Therapeutics The Case for Viking Therapeutics From last Friday: New buy, old friend - Viking Therapeutics (VKTX- $31.11) More on Monday. By Doug Kass Mar 6, 2026 9:45 AM EST --- The quick case for Viking Therapeutics VKTX: * Top-tier efficacy and safety into Phase 3 trials * The company has the same type of molecule as the superior ...
Read in context ›Things I Did Today Here are today's things: * Buy SPY at $670.50 (S&P cash -105 handles) and sold SPY calls (against on rally at -61 handles lower in S&P cash) for a nice profit. * Buy QQQ at $599.90 (S&P cash -105 handles) and sold QQQ calls (against on rally at -61 handles ...
Read in context ›Exploring a New/Old Trade New buy, old friend - Viking Therapeutics VKTX. More on Monday.
Read in context ›Two Hours into the Trading Day Equities have moved slightly higher since my last post. Viking Therapeutics VKTX is moving some 5% higher in the first two hours of trading. Clinical stage competitor AltImmune ALT posted mixed data from a mid-stage tria…
Read in context ›